Key Takeaways Vigil Neuroscience shares more than tripled Thursday after the company reached a deal to be acquired by Sanofi.French pharmaceutical giant Sanofi agreed to pay $8.00 per share in cash at closing,

Sanofi (NASDAQ:SNY) said Wednesday it agreed to acquire clinical-stage biotechnology company Vigil Neuroscience (NASDAQ:VIGL) for $470M in cash, potentially reaching $600M with milestone payments. Following a trading halt,

Vigil’s shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 - - Acquisition expected to strengthen development path for the oral small molecule TREM2 agonist program,